Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-15
2010-06-08
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S383000, C548S136000, C548S262400
Reexamination Certificate
active
07732468
ABSTRACT:
Disclosed are 3-aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related compounds thereof, represented by the Formula I:wherein Ar1, Ar2, and X are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
REFERENCES:
patent: 7144876 (2006-12-01), Cai et al.
patent: 2004/0167192 (2004-08-01), Solow-Cordero et al.
patent: 2004-010548 (2004-01-01), None
Kulkarni et al., Asian Journal of Chemistry (2003), 15(2), p. 621-624, (Abstract from STN).
Invidata, F.P., et al., “Synthesis and Pharmacological Properties of 6-Substituted 3-(Pyridine -4-YL)-1,2,4-Triazole [3,4-b][1,3,4,]Thiadiazoles,”IL Farmaco 46:1489-1495, Societá Chimica Italiana (1991).
Nadkarni, B.A., et al., “Synthesis and Anthelmintic Activity of 3,6-Disubstituted-7H-s-triazolo(3,4-b)(1,3,4)thiadiazines,”Arzneimittel-Forschung 51:569-573, Editio Cantor Verlag (2001).
Xu, P.-F., et al., “Synthesis of Triazoles, Oxadiazoles and Condensed Heterocyclic Compounds Containing Cinchopheny and Studies on Biological Activity of Representative Compounds,”J. Chin. Chem. Soc. 51:315-319, The Chemical Society, Taipei, Taiwan, Republic of China (2004).
Zhang, Z.-Y., and Xin, C., “Studies on Condensed Heteocyecic Compounds. I. Synthesis and Antibacterial Activity of 3-(4′-Pyridyl)-6-aryl-s-triazolo[3,4-b]-1,3,4-thiadiazoles,”Acta Chim. Sin. 49:513-520, Science Press (1991) (English language abstract listed on the end page).
Dialog File 351, Accession No. 14013736, Derwent WPI English language abstract for JP 2004 010548 A (listed on accompanying PTO/SB/08A as document FP1).
Dincer, M., et al., “6-Phenyl-3-(4-pyridyl)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole,”Acta. Crystallogr. C 61:o665-o667, Blackwell Publishing (2005).
Zhang, Q., et al., “Redifferentiation of human hepatoma cell induced by 6-(p-chlorophenyl)-3-[1-(p-chlorophenyl)-5-methyl-1H-1,2,3-triazol-4-yl]-s-triazolo[3,4-b]-1,3,4-thiadiazole (TDZ),”Pharmazie 60:378-382, Govi-Verlag Pharmazeutischer Verlag (2005).
International Search Report for International Application PCT/US07/23957, mailed on Apr. 23, 2008, United States Patent Office, Alexandria, Virginia.
Cai Sui Xiong
Drewe John A.
Sirisoma Nilantha Sudath
Zhang Han-Zhong
Chu Yong
Cytovia, Inc.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
3-aryl-6-aryl-[ 1,2,4]triazolo[3,4- b ][1,3,4]thiadiazoles... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-aryl-6-aryl-[ 1,2,4]triazolo[3,4- b ][1,3,4]thiadiazoles..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-aryl-6-aryl-[ 1,2,4]triazolo[3,4- b ][1,3,4]thiadiazoles... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4150891